Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
7.78
+0.75 (10.67%)
At close: Feb 20, 2026, 4:00 PM EST
7.64
-0.14 (-1.80%)
After-hours: Feb 20, 2026, 7:54 PM EST
Ocular Therapeutix Employees
Ocular Therapeutix had 325 employees as of December 31, 2025. The number of employees increased by 51 or 18.61% compared to the previous year.
Employees
325
Change (1Y)
51
Growth (1Y)
18.61%
Revenue / Employee
$159,849
Profits / Employee
-$818,274
Market Cap
1.69B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 325 | 51 | 18.61% |
| Dec 31, 2024 | 274 | 7 | 2.62% |
| Dec 31, 2023 | 267 | -7 | -2.55% |
| Dec 31, 2022 | 274 | 46 | 20.18% |
| Dec 31, 2021 | 228 | 47 | 25.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 952 |
| Intellia Therapeutics | 403 |
| Biohaven | 256 |
| uniQure | 209 |
| Relay Therapeutics | 188 |
| Celldex Therapeutics | 186 |
| Capricor Therapeutics | 160 |
| Monte Rosa Therapeutics | 147 |
OCUL News
- 1 day ago - Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 3 days ago - Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript - Seeking Alpha
- 3 days ago - Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial - Reuters
- 7 days ago - Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - GlobeNewsWire
- 14 days ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive - Seeking Alpha
- 2 months ago - Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug - Benzinga
- 3 months ago - Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript - Seeking Alpha